News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
215 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39122)
2019 (51337)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42567)
2024 (37443)
2025 (33092)
2026 (3137)
Month
January (2488)
February (2603)
March (3228)
April (2950)
May (3962)
June (3500)
July (2854)
August (3142)
September (3205)
October (3540)
November (3386)
December (2332)
Day
1 (247)
2 (234)
3 (123)
4 (6)
5 (2)
6 (157)
7 (294)
8 (215)
9 (227)
10 (147)
11 (6)
12 (2)
13 (213)
14 (201)
15 (161)
16 (149)
17 (68)
19 (2)
20 (132)
21 (113)
22 (70)
23 (4)
24 (6)
26 (9)
27 (154)
28 (186)
29 (127)
30 (131)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
19
20
21
22
23
24
26
27
28
29
30
Deals
German Biotech InflaRx Snags $100M in IPO
The company announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share.
November 8, 2017
·
2 min read
Business
Egalet Announces Third Quarter 2017 Financial Results
Egalet today announced financial results for the third quarter ended September 30, 2017.
November 8, 2017
·
18 min read
Business
Bracket Strengthens Global Growth and Development Strategy With New CCO, Christopher Crucitti
Crucitti joins Bracket as an experienced commercial leader in clinical and R&D services.
November 8, 2017
·
3 min read
Business
Merrimack Reports Third Quarter 2017 Financial Results
Merrimack today announced its third quarter 2017 financial results for the period ended September 30, 2017.
November 8, 2017
·
17 min read
Business
Oncolytics Biotech Announces 2017 Third Quarter Results
Oncolytics Biotech today announced its financial results and operational highlights for the quarter ended September 30, 2017.
November 8, 2017
·
24 min read
Business
RXi Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
A live audio webcast will begin today at 4:30 p.m. ET. The webcast link is available under the “Investors - Events and Presentations” section of the Company’s website, www.rxipharma.com.
November 8, 2017
·
16 min read
Business
Labcyte and FIMM Extend Personalized Medicine Collaboration
Labcyte and the Institute for Molecular Medicine Finland announced they are extending their personalized medicine collaboration to include multiple new applications that leverage the unique capabilities of Labcyte’s Echo liquid handler and Access™ automation platform.
November 8, 2017
·
3 min read
Drug Development
Verseon’s Novel Anticancer Agents for Multidrug Resistant Tumors Presented at BIO-Europe 2017
The data suggest that these drug candidates may be especially well-suited for the treatment of solid tumors resistant to existing chemotherapy agents.
November 8, 2017
·
3 min read
Genetown
ArQule Announces $9.5 Million Private Placement of Preferred Stock
The Pontifax Group pursuant to which the Company raised gross proceeds of $9.5 million through the sale of approximately 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants covering 2,260 shares of Series A Preferred (Warrants).
November 8, 2017
·
8 min read
Business
Ophthotech Reports Third Quarter 2017 Financial and Operating Results
As of September 30, 2017, the Company had $180.2 million in cash and cash equivalents.
November 8, 2017
·
10 min read
Previous
3 of 22
Next